title: Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome?
abstract: A total of 28 women scheduled for in-vitro fertilization used buserelin and human menopausal gonadotrophin (HMG) for ovarian stimulation. One group (I) of 17 women was given human chorionic gonadotrophin (HCG 10,000 IU) to trigger ovulation, but the resulting embryos were electively cryopreserved because of the risk (serum oestradiol greater than or equal to 3500 pg/ml) of developing the ovarian hyperstimulation syndrome (OHSS). Six women continued the buserelin therapy in the luteal phase and eleven did not. In group II (n = 11), the HMG injections were discontinued because of an exaggerated ovarian response and the HCG was omitted. Six of these women continued the buserelin injections until the onset of menses and five did not. In both groups, the ovarian response to induction of ovulation (serum oestradiol concentrations and number of follicles) was similar for those who did or did not continue buserelin therapy. There was no difference in the rate of ovarian quiescence (weekly fall in serum oestradiol concentration following the stimulation) between those women who did or did not continue the buserelin therapy in either group. The serum luteinizing hormone concentrations remained low in all women in both groups. We conclude that the omission of buserelin therapy after discontinuing the HMG in women at risk of developing OHSS does not affect subsequent ovarian quiescence.
authors.affiliation: Regional IVF Unit, St Mary's Hospital, Manchester, UK.
authors.forename: I
authors.initials: I
authors.lastname: Wada
authors.forename: P L
authors.initials: PL
authors.lastname: Matson
authors.forename: G
authors.initials: G
authors.lastname: Horne
authors.forename: P
authors.initials: P
authors.lastname: Buck
authors.forename: B A
authors.initials: BA
authors.lastname: Lieberman
mesh_terms: D000328:Adult; D002064:Buserelin / Q000008:administration & dosage* / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000009:adverse effects*; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000008:administration & dosage / Q000627:therapeutic use; D016471:Ovarian Hyperstimulation Syndrome / Q000097:blood / Q000139:chemically induced*; D010062:Ovulation Induction
chemical_list: D006063:Chorionic Gonadotropin; D004958:Estradiol; D008596:Menotropins; D007986:Luteinizing Hormone; D002064:Buserelin